Brunelli M P, Einhorn T A
Department of Orthopaedics, Mount Sinai, Medical Center, New York, NY, USA.
Clin Orthop Relat Res. 1998 Mar(348):15-21.
The current medical treatment for the prevention of fractures in patients with osteoporotic bone, in particular, in patients with fractures involving the hip is discussed. Four drugs, calcium, calcitonin, estrogen, and alendronate have been approved for marketing by the Food and Drug Administration for the treatment of osteoporosis. Each of these drugs has a different mode of action to prevent bone loss and each carries its own side effects which must be weighed against the benefits. The future of medical management of osteoporosis involves designing new drugs that will reduce bone loss, potentially restore bone mass, and show proven efficacy in preventing fractures.
本文讨论了目前用于预防骨质疏松症患者骨折的医学治疗方法，尤其是涉及髋部骨折的患者。四种药物——钙、降钙素、雌激素和阿仑膦酸盐已获美国食品药品监督管理局批准上市用于治疗骨质疏松症。这些药物中的每一种都有不同的预防骨质流失的作用方式，且每种药物都有其自身的副作用，必须在权衡利弊后使用。骨质疏松症医学管理的未来在于研发新的药物，这些药物将减少骨质流失，有可能恢复骨量，并在预防骨折方面显示出已证实的疗效。
